{"entity":{"id":"radioimmunotherapy","kind":"technology","name":"Radio-antibody & radio-ADC","aka":[],"tldr":"Attaching a radioactive atom to an antibody, so an ADC's targeting is used to deliver radiation instead of chemotherapy.","summary":"90Y-ibritumomab (Zevalin) and 131I-tositumomab proved the concept in lymphoma but were commercially abandoned. Renewed interest: 225Ac-labelled antibodies to PSMA (J591), CD33 (lintuzumab), DLL3, HER2, and 177Lu-labelled antibodies. Long antibody half-life is both a dosimetry advantage and a marrow-toxicity problem; pretargeting and fragment approaches address it.","status":"phase-2","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Radioimmunotherapy","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Radioimmunotherapy"}],"tags":["frontier"],"related":["idea-alpha-after-adc","lu-177","ac-225","i-131","y-90"],"indications":[],"sections":[],"technologies":["targeted-alpha-therapy"],"targets":["psma","dll3","her2"],"drugs":[],"companies":["abdera-therapeutics","actinium-pharmaceuticals","convergent-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-biotherapy-and-radiopharmaceuticals"],"dependsOn":["therapy-isotope-supply-chain"],"notes":[],"principle":"A chelator-conjugated antibody or fragment carries 177Lu, 225Ac, 212Pb, or 131I.","strengths":["Any ADC target becomes a radiation target","Bystander crossfire independent of payload chemistry"],"limitations":["Marrow dose from circulating antibody","Manufacturing complexity"]},"route":"/technologies/radioimmunotherapy/","neighbours":{"idea":[{"id":"idea-alpha-after-adc","kind":"idea","name":"Alpha radioligands after ADC failure","route":"/ideas/idea-alpha-after-adc/"},{"id":"idea-caix-theranostics","kind":"idea","name":"CAIX theranostics: 89Zr-girentuximab PET and 177Lu/225Ac-girentuximab therapy","route":"/ideas/idea-caix-theranostics/"},{"id":"idea-pretargeted-alpha-therapy","kind":"idea","name":"Pretargeted alpha radioimmunotherapy","route":"/ideas/idea-pretargeted-alpha-therapy/"}],"isotope":[{"id":"ac-225","kind":"isotope","name":"Actinium-225","route":"/isotopes/ac-225/"},{"id":"i-131","kind":"isotope","name":"Iodine-131","route":"/isotopes/i-131/"},{"id":"lu-177","kind":"isotope","name":"Lutetium-177","route":"/isotopes/lu-177/"},{"id":"y-90","kind":"isotope","name":"Yttrium-90","route":"/isotopes/y-90/"}],"technology":[{"id":"auger-electron-therapy","kind":"technology","name":"Auger-electron therapy","route":"/technologies/auger-electron-therapy/"},{"id":"pretargeted-radioimmunotherapy","kind":"technology","name":"Pretargeted radioimmunotherapy","route":"/technologies/pretargeted-radioimmunotherapy/"},{"id":"sarcophagine-chelation","kind":"technology","name":"Sarcophagine chelation","route":"/technologies/sarcophagine-chelation/"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"},{"id":"therapy-isotope-supply-chain","kind":"technology","name":"Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225)","route":"/technologies/therapy-isotope-supply-chain/"}],"target":[{"id":"dll3","kind":"target","name":"DLL3","route":"/targets/dll3/"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"},{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/"},{"id":"sortilin","kind":"target","name":"Sortilin (SORT1)","route":"/targets/sortilin/"}],"company":[{"id":"abdera-therapeutics","kind":"company","name":"Abdera Therapeutics","route":"/companies/abdera-therapeutics/"},{"id":"actinium-pharmaceuticals","kind":"company","name":"Actinium Pharmaceuticals","route":"/companies/actinium-pharmaceuticals/"},{"id":"convergent-therapeutics","kind":"company","name":"Convergent Therapeutics","route":"/companies/convergent-therapeutics/"}],"journal":[{"id":"cancer-biotherapy-and-radiopharmaceuticals","kind":"journal","name":"Cancer biotherapy & radiopharmaceuticals","route":"/journals/cancer-biotherapy-and-radiopharmaceuticals/"}],"indication":[{"id":"follicular-lymphoma","kind":"indication","name":"Follicular lymphoma","route":"/indications/follicular-lymphoma/"},{"id":"rcc","kind":"indication","name":"Renal cell carcinoma","route":"/indications/rcc/"}],"drug":[{"id":"ibritumomab-tiuxetan","kind":"drug","name":"Ibritumomab tiuxetan","route":"/drugs/ibritumomab-tiuxetan/"},{"id":"i-131-tositumomab","kind":"drug","name":"Iodine-131 tositumomab","route":"/drugs/i-131-tositumomab/"},{"id":"iomab-b","kind":"drug","name":"Iomab-B","route":"/drugs/iomab-b/"},{"id":"tlx-591","kind":"drug","name":"Lutetium-177 rosopatamab tetraxetan","route":"/drugs/tlx-591/"}],"roadmap":[{"id":"radiopharma-roadmap","kind":"roadmap","name":"Radiopharmaceutical roadmap: iodine → lutetium → actinium","route":"/roadmaps/radiopharma-roadmap/"}],"pairing":[{"id":"rituximab-then-ibritumomab-tiuxetan","kind":"pairing","name":"Rituximab pretreatment before ibritumomab tiuxetan (Zevalin)","route":"/pairings/rituximab-then-ibritumomab-tiuxetan/"}]}}